Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: EFS in the two cohorts.

Data availability

Individual participant data will not be shared. For original data, please contact


  1. Young NS. Aplastic Anemia. N Engl J Med. 2018;379:1643–56. e-pub ahead of print 2018/10/26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Georges GE, Doney K, Storb R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2:2020–8. e-pub ahead of print 2018/08/16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3:3123–31. e-pub ahead of print 2019/10/28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kako S, Yamazaki H, Ohashi K, Ozawa Y, Ota S, Kanda Y, et al. Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. Biol Blood Marrow Transpl. 2020;26:445–50. e-pub ahead of print 2019/10/17.

    Article  CAS  Google Scholar 

  5. Xu ZL, Cheng YF, Zhang YY, Mo XD, Han TT, Wang FR, et al. The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transpl. 2021;35:e14160 e-pub ahead of print 2020/11/23.

    Article  CAS  Google Scholar 

  6. Dulley FL, Vigorito AC, Aranha FJ, Sturaro D, Ruiz MA, Saboya R, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transpl. 2004;33:9–13. e-pub ahead of print 2003/10/28.

    Article  CAS  Google Scholar 

  7. Apsel Winger B, Shukla P, Kharbanda S, Keizer RJ, Goswami S, Cowan MJ, et al. The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. Transpl Cell Ther. 2021;27:258 e251–258 e256. e-pub ahead of print 2021/03/31.

    Article  CAS  Google Scholar 

  8. Qin X, Zhu YP, Luo CJ, Zhou M, Huang K, Chen C, et al. Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years. Ann Hematol. 2021;100:2363–73. e-pub ahead of print 2021/05/15.

    Article  CAS  PubMed  Google Scholar 

  9. Xu ZL, Xu LP, Zhang YY, Cheng YF, Mo XD, Wang FR, et al. Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation. Bone Marrow Transpl. 2019;54:1694–1700. e-pub ahead of print 2019/03/25.

    Article  Google Scholar 

  10. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:e526–e536. e-pub ahead of print 2016/10/18.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Xu L-P, Xu Z-L, Wang S-Q, Wu D-P, Gao S-J, Yang J-M, et al. Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study. Sci Bullet. 2022;

Download references


This work was partly supported by National Natural Science Foundation of China (Grant No. 82100227), Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81621001), and The National Key Research and Development Program of China (No. 2017YFA0104500).

Author information

Authors and Affiliations



XJH designed the research; LPX, ZLX and XJ analysed the data and wrote the paper; and all authors, provided patient data and gave final approval for the paper.

Corresponding author

Correspondence to Xiao-Jun Huang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xu, LP., Xu, ZL., Zhang, YY. et al. Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplant 57, 1204–1206 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links